China's CDE Launches "Pioneer Plan" Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing
Policy / Regulatory

China’s CDE Launches “Pioneer Plan” Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing

The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) issued the Pilot Plan for Promoting the Research and Application of New Approach Methodologies (the "Pioneer Plan"),…

BioMarin's Vosoritide Wins NMPA Approval in China – First CNP-Analog Therapy for Pediatric Achondroplasia Enters the World's Largest Rare Bone Disease Market
CompanyDrug

BioMarin’s Vosoritide Wins NMPA Approval in China – First CNP-Analog Therapy for Pediatric Achondroplasia Enters the World’s Largest Rare Bone Disease Market

Merck's KEYTRUDA (Pembrolizumab) Wins NMPA Approval in Early‑Stage High‑Risk TNBC – Label Expansion Beyond PD‑L1 CPS ≥ 20 for China's Only Approved PD‑1 Perioperative Breast Cancer Therapy
CompanyDrug

Merck’s KEYTRUDA (Pembrolizumab) Wins NMPA Approval in Early‑Stage High‑Risk TNBC – Label Expansion Beyond PD‑L1 CPS ≥ 20 for China’s Only Approved PD‑1 Perioperative Breast Cancer Therapy

Novo Nordisk's Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China's Broadest‑Label Long‑Acting Growth Hormone
CompanyDrug

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Novo Nordisk's Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
CompanyDrug

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

FDA Approves AbbVie's Tavapadon as Juvmo for Parkinson's Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfoli
CompanyDrug

FDA Approves AbbVie’s Tavapadon as Juvmo for Parkinson’s Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfolio

Xinhua Pharmaceutical Secures NMPA Registration for Generic Sacubitril/Valsartan Tablets – Entering China's RMB 7.8 Billion Heart Failure Market
CompanyDrug

Xinhua Pharmaceutical Secures NMPA Registration for Generic Sacubitril/Valsartan Tablets – Entering China’s RMB 7.8 Billion Heart Failure Market

SSY Group Secures NMPA Approval for Nimodipine Oral Solution – Bulk Drug‑to‑Formulation Vertical Integration Strengthens Cerebrovascular Portfolio
CompanyDrug

SSY Group Secures NMPA Approval for Nimodipine Oral Solution – Bulk Drug‑to‑Formulation Vertical Integration Strengthens Cerebrovascular Portfolio

Novartis' Rhapsido (Remibrutinib) Wins FDA Approval – First‑in‑Class BTK Inhibitor Becomes First Approved Treatment for Symptomatic Dermographism
CompanyDrug

Novartis’ Rhapsido (Remibrutinib) Wins FDA Approval – First‑in‑Class BTK Inhibitor Becomes First Approved Treatment for Symptomatic Dermographism

Pfizer's TUKYSA Wins FDA Approval for First‑Line Maintenance in HER2+ Metastatic Breast Cancer – Chemotherapy‑Free Tucatinib Combination Delivers 36% Reduction in Progression Risk
CompanyDrug

Pfizer’s TUKYSA Wins FDA Approval for First‑Line Maintenance in HER2+ Metastatic Breast Cancer – Chemotherapy‑Free Tucatinib Combination Delivers 36% Reduction in Progression Risk

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Hangzhou Defand Therapeutics Co., Ltd. (Defand) announced that it has entered into a research collaboration and licensing agreement with Roche (SWX: ROP; OTCMKTS: RHHBY) to jointly discover and develop novel molecular glue degraders (MGDs) targeting multiple therapeutic targets in oncology…

Jiangsu Nhwa Signs Exclusive Global Licensing Deal with Somnivera – Clinical‑Stage Sleep‑Disorder Asset Backed by Up to US$517.5 Million in Potential Value

Jiangsu Nhwa Signs Exclusive Global Licensing Deal with Somnivera – Clinical‑Stage Sleep‑Disorder Asset Backed by Up to US$517.5 Million in Potential Value

CompanyDeals

GeneScience Acquires Global Rights to Megestrol Acetate Oral Suspension from TWi Pharmaceuticals – $100M Deal Transforms Distributor into MAH for Cachexia Therapy

BMS Secures Conditional NMPA Approval for Zenbexus (Iberdomide) – World's First Oral CELMoD Agent Wins China Landmark in Relapsed Multiple Myeloma
CompanyDrug

BMS Secures Conditional NMPA Approval for Zenbexus (Iberdomide) – World’s First Oral CELMoD Agent Wins China Landmark in Relapsed Multiple Myeloma

Roche's Fenebrutinib NDA Accepted for FDA Priority Review – Non‑Covalent BTK Inhibitor Targets Both RMS and PPMS in Landmark MS Filing
CompanyDrug

Roche’s Fenebrutinib NDA Accepted for FDA Priority Review – Non‑Covalent BTK Inhibitor Targets Both RMS and PPMS in Landmark MS Filing

Sanofi and Regeneron Expand Alliance with $8B Next‑Generation Antibody Collaboration – Four Long‑Acting Type 2 Inflammation Programs Added Alongside Dupixent
CompanyDeals

Sanofi and Regeneron Expand Alliance with $8B Next‑Generation Antibody Collaboration – Four Long‑Acting Type 2 Inflammation Programs Added Alongside Dupixent

Shionogi to Acquire IntraBio for $2.0B – Rare Neurodegenerative Disease Platform Anchored by FDA‑Approved AQNEURSA Expands Global Portfolio
CompanyDeals

Shionogi to Acquire IntraBio for $2.0B – Rare Neurodegenerative Disease Platform Anchored by FDA‑Approved AQNEURSA Expands Global Portfolio

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.
M&A and Licensing
Foghorn Therapeutics and Lilly Discontinue FHD‑909 and SMARCA2 Programs – Gene Traffic Control Collaboration Ends After Phase 1 Review
CompanyDeals

Foghorn Therapeutics and Lilly Discontinue FHD‑909 and SMARCA2 Programs – Gene Traffic Control Collaboration Ends After Phase 1 Review

Foghorn Therapeutics Inc. (NASDAQ: FHTX) announced that, following a review of clinical data from the Phase 1 dose‑escalation trial of FHD‑909 (LY4050784), both Foghorn and Eli Lilly and Company (NYSE:…

GE HealthCare to Acquire SOFIE Biosciences for $945M – Bolstering PET Radiopharmaceutical Manufacturing and Securing Phase III FAPI‑74 Asset
CompanyDeals

GE HealthCare to Acquire SOFIE Biosciences for $945M – Bolstering PET Radiopharmaceutical Manufacturing and Securing Phase III FAPI‑74 Asset

Alector Grants Genentech Worldwide Rights to AL050 in $1.27B Deal – Brain‑Penetrant GCase Therapy Targets Neurodegeneration in Parkinson's Disease
CompanyDeals

Alector Grants Genentech Worldwide Rights to AL050 in $1.27B Deal – Brain‑Penetrant GCase Therapy Targets Neurodegeneration in Parkinson’s Disease

CSL Behring and Alentis Therapeutics Forge $1.55B Global Lixudebart Alliance – Anti‑Claudin‑1 Antibody Targets Rare Autoimmune Kidney, Liver, and Lung Diseases
CompanyDeals

CSL Behring and Alentis Therapeutics Forge $1.55B Global Lixudebart Alliance – Anti‑Claudin‑1 Antibody Targets Rare Autoimmune Kidney, Liver, and Lung Diseases

Asieris Pharmaceuticals Inks Exclusive CEVIRA® License with Theramex – First‑in‑Class Cervical Photodynamic Therapy Enters European Commercialization
CompanyDeals

Asieris Pharmaceuticals Inks Exclusive CEVIRA® License with Theramex – First‑in‑Class Cervical Photodynamic Therapy Enters European Commercialization

- Advertisement -
Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances "Closed‑Loop Nerve Bundle Modulation" Platform
CompanyDeals

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances “Closed‑Loop Nerve Bundle Modulation” Platform

Tangzhi Pharma Secures Nearly RMB 100 Million Exclusive Financing from Fengnian Capital – Glyco Raw‑Material Platform Targets ADC and Nucleic‑Acid Drug Boom
CompanyDeals

Tangzhi Pharma Secures Nearly RMB 100 Million Exclusive Financing from Fengnian Capital – Glyco Raw‑Material Platform Targets ADC and Nucleic‑Acid Drug Boom

Medicovestor Completes Seed Funding Round to Advance Next-Generation Antibody and ADC Pipeline – MC004 Naked Antibody Targets FDA IND Filing by Early 2027
CompanyDeals

Medicovestor Completes Seed Funding Round to Advance Next-Generation Antibody and ADC Pipeline – MC004 Naked Antibody Targets FDA IND Filing by Early 2027

Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World's First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development
CompanyDeals

Medinno Pharmaceutical Closes Over RMB 200 Million Series A Led by Sunshine Ronghui Capital – MDI‑1228, World’s First Topical Pan‑JAK/Pan‑Trk Inhibitor, Advances Global Clinical Development

MIIT and Nine Departments Issue China's "15th Five‑Year Plan for Pharmaceutical Industry Development" – Innovative Drug Sector Targeted to Grow Over 20 % Annually Through 2030
Policy / Regulatory

MIIT and Nine Departments Issue China’s “15th Five‑Year Plan for Pharmaceutical Industry Development” – Innovative Drug Sector Targeted to Grow Over 20 % Annually Through 2030

The Ministry of Industry and Information Technology (MIIT), together with nine other departments, formulated and issued the "15th Five‑Year Plan for Pharmaceutical Industry Development" (the "Plan"), setting quantitative industry targets…

China's NMPA Unveils Draft Regulations on Radiopharmaceuticals – Public Consultation Open Through October 20 With Priority Review for Urgent‑Demand Products
Policy / Regulatory

China’s NMPA Unveils Draft Regulations on Radiopharmaceuticals – Public Consultation Open Through October 20 With Priority Review for Urgent‑Demand Products

Three Oncology Assets Join CDE Pilot Programs – ICP‑B794 and Aponermin Enter "Care Program – Extension" While GH56 Advances Pediatric Development
Policy / Regulatory

Three Oncology Assets Join CDE Pilot Programs – ICP‑B794 and Aponermin Enter “Care Program – Extension” While GH56 Advances Pediatric Development

China Orders Whole‑Class Listing of "Orphine‑Type Substances" in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026
Policy / Regulatory

China Orders Whole‑Class Listing of “Orphine‑Type Substances” in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026

More News

Biocause Heilen Wins NMPA Approval for Ibuprofen Arginine Granules – Enhanced‑Solubility NSAID Enters China's OTC Analgesic Market
Others

Biocause Heilen Wins NMPA Approval for Ibuprofen Arginine Granules – Enhanced‑Solubility NSAID Enters China’s OTC Analgesic Market

BGM0504 Delivers Up to 19.2% Weight Loss in Phase III at EASD 2026 – CR Sanjiu and BrightGene's GLP‑1/GIP Dual Agonist Meets All Endpoints in Chinese Population
CompanyDrug

BGM0504 Delivers Up to 19.2% Weight Loss in Phase III at EASD 2026 – CR Sanjiu and BrightGene’s GLP‑1/GIP Dual Agonist Meets All Endpoints in Chinese Population

Zhongsheng's ZSP1601 Granted Breakthrough Therapy Designation by China's CDE – First‑in‑Class MASH Drug with Positive Phase IIb Data Enters Accelerated Review
CompanyDrug

Zhongsheng’s ZSP1601 Granted Breakthrough Therapy Designation by China’s CDE – First‑in‑Class MASH Drug with Positive Phase IIb Data Enters Accelerated Review

GeneScience's GenSci155 Wins NMPA Clinical Trial Approval – Long‑Acting IGF‑1 Analog Targets Bronchopulmonary Dysplasia and Rare Growth Disorder
CompanyDrug

GeneScience’s GenSci155 Wins NMPA Clinical Trial Approval – Long‑Acting IGF‑1 Analog Targets Bronchopulmonary Dysplasia and Rare Growth Disorder

Betta Pharmaceuticals Secures FDA IND Approval for BPI‑572270 Capsules – Novel Pan‑RAS "Non‑Degradative Molecular Glue" Inhibitor Advances into U.S. Clinical Trials
CompanyDrug

Betta Pharmaceuticals Secures FDA IND Approval for BPI‑572270 Capsules – Novel Pan‑RAS “Non‑Degradative Molecular Glue” Inhibitor Advances into U.S. Clinical Trials

Allist's Firmonertinib Misses Primary PFS Endpoint in Phase 3 FURVENT Trial – 60% Response Rate and OS Trend Keep EGFR Exon 20 Insertion NSCLC Program Alive
CompanyDrug

Allist’s Firmonertinib Misses Primary PFS Endpoint in Phase 3 FURVENT Trial – 60% Response Rate and OS Trend Keep EGFR Exon 20 Insertion NSCLC Program Alive

Ribo Life Science Opens Automated Intelligent Drug Screening Center – A Key Leap in AI‑Powered siRNA Drug Discovery
Company

Ribo Life Science Opens Automated Intelligent Drug Screening Center – A Key Leap in AI‑Powered siRNA Drug Discovery

CSPC to Unveil Data From 8 Oncology Trials at ESMO Congress 2026 – Anbenitamab Phase III Results Headline Two Late‑Breaking Abstracts
CompanyDrug

CSPC to Unveil Data From 8 Oncology Trials at ESMO Congress 2026 – Anbenitamab Phase III Results Headline Two Late‑Breaking Abstracts

Show More